Roberts Mitani: An Alternative Strategy for Life Science Investing
This article was originally published in Start Up
At a time when bankers and investors, driven by quarter-to-quarter results, are always on the look-out for the next deal, Roberts Mitani has a different philosophy for investing in life sciences. "Our firm is built on developing long-term relationships with clients," says principal Bruce Roberts. "Building long-term relationships with clients allows us to be creative; for example, we can work on smaller transactions if that's what the client needs, because we receive warrants for our participation, and, unlike other banks, we know we'll be sticking around to witness the benefits of that kind of deal." The firm is also able to integrate both US and overseas investors.
You may also be interested in...
While innovation in interventional cardiology has historically come from small companies, industry consolidation and a flattening of technology has, in recent years, given the edge to large suppliers, which now all but dominate the field. Drug-eluting stents, which require huge resource expenditures, seem to epitomize this shift of interventional cardiology to a big-company game. But in at least one highly promising area--bifurcated lesions--small companies continue to have the edge in developing a device to effectively treat this significant unmet clinical need. Encouraging for these smaller companies is the fact that the critical technology hurdle in treating bifurcations is primarily mechanical, not biological, enabling new approaches that can potentially complement, not compete against, drug-coated stents.
At In3 West, a medical device conference held in Las Vegas recently, Windhover Information convened a panel of venture investors to ask them what's in store for device companies seeking investments in the near future, and to address one nagging question: whether or not the heady funding levels of 2007 are sustainable, or even desirable. Certainly exits have become more challenging; consolidation has removed certain would-be acquirers and the IPO market has become more demanding; no company will get out there without at least $30 to $40 million in revenues, several on the panel felt. Others were feeling the pressure of having to carry portfolio companies for even longer periods of time; more complex technologies, lag times at the FDA, and the need to get companies not only to the commercial stage but to a revenue ramp were pushing up the number of years to an exit and total investment dollars. Many were optimistic that early stage deals, exits by acquisition and other unusual phenomena would continue to happen; but selectivity was the theme of the day.
Venture debt has become an increasingly popular financing option particularly among device companies. But, if not used properly, it can help sink rather than save a start-up.